Literature DB >> 26123801

Control of Mycobacterial Infections in Mice Expressing Human Tumor Necrosis Factor (TNF) but Not Mouse TNF.

Maria L Olleros1, Leslie Chavez-Galan2, Noria Segueni3, Marie L Bourigault3, Dominique Vesin1, Andrey A Kruglov4, Marina S Drutskaya5, Ruth Bisig1, Stefan Ehlers6, Sahar Aly6, Kerstin Walter7, Dmitry V Kuprash8, Miliana Chouchkova9, Sergei V Kozlov10, François Erard3, Bernard Ryffel3, Valérie F J Quesniaux3, Sergei A Nedospasov11, Irene Garcia12.   

Abstract

Tumor necrosis factor (TNF) is an important cytokine for host defense against pathogens but is also associated with the development of human immunopathologies. TNF blockade effectively ameliorates many chronic inflammatory conditions but compromises host immunity to tuberculosis. The search for novel, more specific human TNF blockers requires the development of a reliable animal model. We used a novel mouse model with complete replacement of the mouse TNF gene by its human ortholog (human TNF [huTNF] knock-in [KI] mice) to determine resistance to Mycobacterium bovis BCG and M. tuberculosis infections and to investigate whether TNF inhibitors in clinical use reduce host immunity. Our results show that macrophages from huTNF KI mice responded to BCG and lipopolysaccharide similarly to wild-type macrophages by NF-κB activation and cytokine production. While TNF-deficient mice rapidly succumbed to mycobacterial infection, huTNF KI mice survived, controlling the bacterial burden and activating bactericidal mechanisms. Administration of TNF-neutralizing biologics disrupted the control of mycobacterial infection in huTNF KI mice, leading to an increased bacterial burden and hyperinflammation. Thus, our findings demonstrate that human TNF can functionally replace murine TNF in vivo, providing mycobacterial resistance that could be compromised by TNF neutralization. This new animal model will be helpful for the testing of specific biologics neutralizing human TNF.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26123801      PMCID: PMC4534677          DOI: 10.1128/IAI.00743-15

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

Review 1.  Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice.

Authors:  Caroline Winsauer; Andrey A Kruglov; Anna A Chashchina; Marina S Drutskaya; Sergei A Nedospasov
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-24       Impact factor: 7.638

2.  Soluble TNFRp75 regulates host protective immunity against Mycobacterium tuberculosis.

Authors:  Roanne Keeton; Nasiema Allie; Ivy Dambuza; Brian Abel; Nai-Jen Hsu; Boipelo Sebesho; Philippa Randall; Patricia Burger; Elizabeth Fick; Valerie F J Quesniaux; Bernhard Ryffel; Muazzam Jacobs
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

Review 3.  Prospects for tuberculosis elimination.

Authors:  Christopher Dye; Philippe Glaziou; Katherine Floyd; Mario Raviglione
Journal:  Annu Rev Public Health       Date:  2012-12-14       Impact factor: 21.981

4.  A major event for new tuberculosis vaccines.

Authors:  Christopher Dye; Paul E M Fine
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321

5.  Upregulation of p75 tumor necrosis factor alpha receptor in Mycobacterium avium-infected mice: evidence for a functional role.

Authors:  A Corti; L Fattorini; O F Thoresen; M L Ricci; A Gallizia; M Pelagi; Y Li; G Orefici
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

6.  Long-term safety study of infliximab in moderate-to-severe chronic obstructive pulmonary disease.

Authors:  Stephen I Rennard; Susan K Flavin; Prasheen K Agarwal; Kim Hung Lo; Elliot S Barnathan
Journal:  Respir Med       Date:  2012-12-14       Impact factor: 3.415

7.  Efficacy of membrane TNF mediated host resistance is dependent on mycobacterial virulence.

Authors:  I Dambuza; N Allie; L Fick; N Johnston; C Fremond; J Mitchell; V F J Quesniaux; B Ryffel; M Jacobs
Journal:  Tuberculosis (Edinb)       Date:  2007-10-22       Impact factor: 3.131

8.  Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.

Authors:  Jung-Wan Yoo; Kyung-Wook Jo; Bo-Hyung Kang; Mi Young Kim; Bin Yoo; Chang-Keun Lee; Yong-Gil Kim; Suk-Kyun Yang; Jeong-Sik Byeon; Kyung-Jo Kim; Byong Duk Ye; Tae Sun Shim
Journal:  Eur Respir J       Date:  2014-08-07       Impact factor: 16.671

9.  Membrane-bound TNF induces protective immune responses to M. bovis BCG infection: regulation of memTNF and TNF receptors comparing two memTNF molecules.

Authors:  Maria L Olleros; Dominique Vesin; Ruth Bisig; Marie-Laure Santiago-Raber; Sonia Schuepbach-Mallepell; George Kollias; Olivier Gaide; Irene Garcia
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

10.  Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection.

Authors:  Noria Segueni; Solenne Vigne; Gaby Palmer; Marie-Laure Bourigault; Maria L Olleros; Dominique Vesin; Irene Garcia; Bernhard Ryffel; Valérie F J Quesniaux; Cem Gabay
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

View more
  13 in total

Review 1.  Animal Models for Tuberculosis in Translational and Precision Medicine.

Authors:  Lingjun Zhan; Jun Tang; Mengmeng Sun; Chuan Qin
Journal:  Front Microbiol       Date:  2017-05-04       Impact factor: 5.640

2.  Cytokine neutralization at specific cellular source : A new therapeutic paradigm?

Authors:  A A Kruglov; S A Nedospasov
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

3.  [Cytokine neutralization at specific cellular source : A new therapeutic paradigm? German Version].

Authors:  A A Kruglov; S A Nedospasov
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

4.  Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source.

Authors:  Grigory A Efimov; Andrei A Kruglov; Zoya V Khlopchatnikova; Fedor N Rozov; Vladislav V Mokhonov; Stefan Rose-John; Jürgen Scheller; Siamon Gordon; Martin Stacey; Marina S Drutskaya; Sergei V Tillib; Sergei A Nedospasov
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-02       Impact factor: 11.205

5.  Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.

Authors:  Kerstin Walter; Julia Kokesch-Himmelreich; Axel Treu; Franziska Waldow; Doris Hillemann; Nikolas Jakobs; Ann-Kathrin Lemm; Dominik Schwudke; Andreas Römpp; Christoph Hölscher
Journal:  Antimicrob Agents Chemother       Date:  2021-12-06       Impact factor: 5.938

6.  VHH-Based Bispecific Antibodies Targeting Cytokine Production.

Authors:  Maxim A Nosenko; Kamar-Sulu N Atretkhany; Vladislav V Mokhonov; Grigory A Efimov; Andrey A Kruglov; Sergei V Tillib; Marina S Drutskaya; Sergei A Nedospasov
Journal:  Front Immunol       Date:  2017-09-01       Impact factor: 7.561

7.  Transmembrane TNF and Partially TNFR1 Regulate TNFR2 Expression and Control Inflammation in Mycobacterial-Induced Pleurisy.

Authors:  Husnu Uysal; Leslie Chavez-Galan; Dominique Vesin; Guillaume Blaser; Mahdia Benkhoucha; Bernhard Ryffel; Valérie F J Quesniaux; Irene Garcia
Journal:  Int J Mol Sci       Date:  2018-07-04       Impact factor: 5.923

8.  TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation.

Authors:  Kamar-Sulu N Atretkhany; Maxim A Nosenko; Violetta S Gogoleva; Ruslan V Zvartsev; Zhihai Qin; Sergei A Nedospasov; Marina S Drutskaya
Journal:  Front Immunol       Date:  2016-04-19       Impact factor: 7.561

9.  Innate myeloid cell TNFR1 mediates first line defence against primary Mycobacterium tuberculosis infection.

Authors:  Noria Segueni; Sulayman Benmerzoug; Stéphanie Rose; Amandine Gauthier; Marie-Laure Bourigault; Flora Reverchon; Amandine Philippeau; François Erard; Marc Le Bert; Hélène Bouscayrol; Thierry Wachter; Irène Garcia; George Kollias; Muazzam Jacobs; Bernhard Ryffel; Valerie F J Quesniaux
Journal:  Sci Rep       Date:  2016-03-02       Impact factor: 4.379

10.  Altered composition and functional profile of high-density lipoprotein in leprosy patients.

Authors:  Robertha Mariana R Lemes; Carlos Adriano de M E Silva; Maria Ângela de M Marques; Georgia C Atella; José Augusto da C Nery; Maria Renata S Nogueira; Patricia S Rosa; Cléverson T Soares; Prithwiraj De; Delphi Chatterjee; Maria Cristina V Pessolani; Cristiana S de Macedo
Journal:  PLoS Negl Trop Dis       Date:  2020-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.